A recent study, published in the New England Journal of Medicine, has found that a new drug, lecanemab, may slow down the cognitive deterioration in Alzheimer’s patients, which could offer novel treatments for the neurodegenerative disease. The study concluded that lecanemab would be a positive step in treating patients with Alzheimer’s.
About the Study
Since Alzheimer’s is a complex disease with numerous underlying causes connected to the biology of aging, the Alzheimer’s Drug Discovery Foundation (ADDF) has long maintained that a combination drug approach is necessary, stated the study. The findings of this recent study were presented at the 15th edition of the Clinical Trials on Alzheimer’s Disease Conference (CTAD).
Amyloid-clearing drugs are one component of the solution. But there is a need to develop a new generation of drugs targeting all facets of the biology of aging, in order to address the full spectrum of underlying pathologies contributing to the disease, according to the study.
Also read: Expert Explains Difference Between Alzheimer’s Disease And Dementia
Amyloid beta, a type of protein found in the brain, is the first factor in Alzheimer’s disease. This protein begins to accumulate into plaques more than two decades before people experience their first neurological issues. Tau tangles, a brain protein start forming after the amyloid buildup. In this, cognitive deterioration follows after tissues in the affected areas begin to wither and die.
The study stated that new and easy-to-use diagnostic techniques can aid in identifying the exact causes of Alzheimer’s in people. This would enhance clinical trials and enable precision in treatment.
Also read: Expert Shares Tips For Alzheimer’s Management At Home For The Elderly
The study results are encouraging and give a clear picture of when treatments will enable patients to maintain their independence for years longer—possibly for the rest of their lives—rather than just for a few more weeks or months.